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Balkwill et al. (1980) observed that human
leukocyte interferon (IFN) from lymphoblastoid
cells prevented 2/3 human mammary carcinomas
from growing as xenografts in genetically athymic
nu/nu mice, but failed to slow the growth once the
tumours had been established. Subsequently,
Balkwill et al. (1982) found a mammary tumour,
the growth of which as a xenograft was stopped by
IFN-a when given 2 or 3 weeks after implantation.
We failed to observe any effect of a highly purified
human IFN-cx on a human malignant melanoma
xenograft (HX34; Selby et al., 1980), a human lung
adenocarcinoma xenograft (HX70; Shorthouse et
al., 1980) and a xenograft of acute myeloid
leukaemia (AML) cells in immunodeprived mice
(Table I). The present experiments differed from
those carried out by Balkwill et al. (1980) not only
in the type of tumour employed, but also in the
source of IFN-a and the nature of the murine host.
We used IFN-a2 produced in E. coli by direct
Table I Effect ofinterferon on s.c. human tumour xenografts
Recipient: Thymectomised-total-body irradiated CBA mice: these mice are leukopenic for
the first 7 days but a cross-species effect of IFN on host leukocytes would neither be
detectable nor expected in this system. (Grafting procedures as described in Palu et al., 1979;
Selby et al., 1980; & Shorthouse et al., 1980).
Interferon: 107ukg- per day i.p. starting one day before tumour implant for 14 days. No
evidence oftoxicity at this dose.
Incidence Average volume (mm3)
Tumour oftumours at day 18 (±s.e.)
Adenocarcinoma of Exp. 1 Control 8/8 295+44a
lung (HX70): IFN 10/10 178+29a
s.c. transplant
from established
xenograft line Exp. 2 Control 10/10 153+33
IFN 10/10 186+24
Melanoma (HX34):
s.c. transplant Control 10/10 442+114
from established IFN 7/8 473+ 179
xenograft line
AML cells (2 x 107
s.c.) taken from Control 17/20 98+10
peripheral blood IFN 19/20 106+ 8
and stored in
liquid N2
aGrowth rate from Day 18 to Day 25 is the same in both groups.
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expression of cloned DNA while Balkwill et al.
(1982) used IFN isolated from tissue culture
supernatants. Both preparations were of
comparable purity with a biological activity in the
range of 108umg-t (Wetzel et al., 1981). While not
chemically identical, the biological properties of
different preparations of IFN-a are extremely
similar (De Grado et al., 1982) and there is little
reason to attribute our inability to demonstrate an
effect of IFN on human tumour xenografts to a
difference in the IFN used. The dose administered
by us (107ukg-' per day i.p.) was 10 times greater
than the 2 x 1iO u per mouse per day s.c. used by
Balkwill et al. (1980) to prevent take and equal to
the dose (i.e. 2 x 105u per mouse per day s.c.)
needed to stop the growth of the established
mammary carcinoma. The other difference is in the
nature of the immunosuppressed mice used to grow
the xenografts. Balkwill et al. (1980, 1982)
employed nu/nu mice whereas in our experiments
the human tumours were grown in CBA mice
deprived of T-cells by thymectomy at 4 weeks of
age and 9Gy total body irradiation at 8 weeks, the
lethal effects of which were prevented by pre-
treatment with 200mgkg-' Ara-C (Millar et al.,
1978).
At the time when the human tumours were
implanted in these irradiated mice the animals were
leukopenic. Again, however, this difference is
unlikely to account for the failure to demonstrate
an effect of human IFN-a on the tumour xeno-
grafts used by us since Balkwill et al. (1982) have
provided convincing evidence that the effect
observed by them is a direct one of the IFN on the
mammary tumour cells. The species specificity of
the action of IFN is such that no effect on host
resistance mechanisms (e.g. NK) would have been
expected. In their experiments the human IFN-a
did not stimulate the activity of murine NK cells,
nor did it induce 2-5 adenylic acid synthetase in
mouse tissues, but it raised this enzyme in the
human carcinoma xenograft following
administration of IFN to nu/nu mice.
The dose of highly purified human IFN-a used in
these experiments, 10iukg-' per day, caused no
detectable toxicity in the mice and it would have
been possible to give substantially greater amounts.
However, on a weight basis the protocol employed
is 3 times the dose found by Rohatiner et al.
(1982) to be maximally tolerated in man, and over
50 times the human dose used by Priestman (1980).
In the first experiment (Table I) IFN caused a
slight slowing of the growth of the adenocarcinoma
of lung, which was significant at the P<0.05 level.
However, in a second experiment no such effect
was noted. The melanoma grows in immuno-
deprived mice both s.c. and when given i.v. in the
lung (Table II); IFN had no effect on the growth at
either site. In the majority of the cell populations
that have been studied (Alexander, 1982) acute
myeloid leukaemia (AML) cells, taken from the
blood of patients with a blood cell separator, grow
in CBA mice that have been immunosuppressed by
thymectomy and total body irradiation. However,
almost invariably after 2-3 weeks the local tumours
which are made up of >90% of human cells regress
spontaneously (Palu et al., 1979).
Table II Effect of interferon on the lethality of human
melanoma xenografts grown as lung tumours
4 x 106 melanoma cells injected i.v. (HX34)
Dead by 90 days Median day ofdeath
Control 4/5 44 days
IFN 5/5 42 days
(all deaths due to multiple lung tumours).
Surface marker and histochemical studies (Palu et
al., 1979; Forbes et al., 1981) indicate that the
regression is associated with maturation of the
AML cells; however, this process is not hastened by
administration of IFN-ac under the conditions of the
experiment described in Table I.
No other tumour xenografts, including the lung
adenocarcinoma (Shorthouse et al., 1980) and
melanoma (Selby et al., 1980) treated with IFN,
regressed spontaneously in these immunodeprived
mice.
We wish to thank Dr J.A. Waitz of the Scherring
Corporation (Bloomfield, N.J., U.S.A.) for providing the
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